Targeted Therapies for Hepatocellular Carcinoma
نویسندگان
چکیده
منابع مشابه
Biomarkers for novel targeted therapies of hepatocellular carcinoma.
Increasing insights into molecular alterations of signalling pathways have led to the development of specific targeted therapies for cancer. Due to the high specificity of monoclonal antibodies or small molecule inhibitors, identification of patients who will benefit from these therapeutics is crucial for treatment success. Furthermore, as classical endpoints of clinical trials are not fully ap...
متن کاملTargeted Therapies in the Treatment of Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common liver cancer and the third leading cause of cancer death. It has been a major worldwide health problem with more new cases being diagnosed each year. The current available therapies for patients with advanced HCC are extremely limited. Therefore, it is of great clinical interests to develop more effective therapies for systemic treatment of adva...
متن کاملInterventional therapies for hepatocellular carcinoma
Hepatocellular carcinoma is the third most common cause of cancer-related death. In the past few years, staging systems have been developed that enable patients to be stratified into treatment algorithms in a multidisciplinary setting. Several of these treatments involve minimally invasive image-guided therapy that can be performed by radiologists.
متن کاملTransarterial Therapies for Hepatocellular Carcinoma.
BACKGROUND The treatment of hepatocellular carcinoma (HCC) is still a major health issue because of its increasing incidence and because of the complexity of its management. Transarterial embolization (TAE) and transarterial chemoembolization (TACE) are two widely used locoregional therapies in the treatment of HCC, especially for unresectable intermediate and advanced HCCs. SUMMARY The moder...
متن کاملIntratumor heterogeneity in hepatocellular carcinoma Running title: Implications for tumor classifications and targeted therapies
Financial support: This work was supported by the following grants: A grant from the TheilerHaag Stiftung, Zurich to AW and LF. Grants from the Krebsliga Schweiz (Oncosuisse), Promedica Stiftung, the „Julius Müller Stiftung“, and from the “Kurt and Senta Herrmann Stiftung”, Vaduz, Lichtenstein to AW and MH. MH is also supported by an ERC Starting grant “LiverCancerMechanism”, the Hofschneider f...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Gastroenterology
سال: 2011
ISSN: 0016-5085
DOI: 10.1053/j.gastro.2011.03.006